

**List Of Malaria Pharmaceutical Products
classified according to the Global Fund Quality Assurance Policy**

Edition: Version 123 - 05-Feb-2025

The list is an overview of pharmaceutical products subject to the Global Fund Quality Assurance Policy that are listed in National and/or WHO standard treatment guidelines and classified according to the various options (A, B, C and ERP reviewed) defined in the Global Fund Quality Assurance Policy (Nov 2023). The list is developed as a tool to assist Principal Recipients (PR) of Global Fund grants to identify the status of finished pharmaceutical products according to the Global Fund Quality Assurance Policy.

The pharmaceutical products are classified based on the following information

A classified product - Listed on WHO prequalification list;

B classified product - Stringent NDRA Registration letter/Marketing Authorization;

C classified product - Authorised for use by WLA if the scope of listing includes the marketing authorisation function as published and regularly updated in the WHO website

ERP reviewed product- Permitted for time-limited procurement based on advice by the Expert Review Panel (ERP);

Please note that the list is not an exhaustive list. A PR can procure product(s) not listed in the current list as long as PR demonstrates that the product is compliant with the Global Fund Quality Assurance Policy.

The Global Fund list includes the following information:

- "Important Notes" for helpful information;

- A, B, C and ERP reviewed products;

- Period validity of the ERP reviewed products;

- "+" means combination product, both fixed-dose combination (co-formulated) and co-packaged product (i.e. co-bliester)

- [A+B]+C means A and B are in fixed-dose formulation and C is co-packaged

YELLOW signifies a new entry; **PINK** signifies modification of an existing entry.

For more information, please look at:

<https://www.theglobalfund.org/en/sourcing-management/quality-assurance/>.

Expert Review Panel (ERP): Expert Review Panel is an independent technical body composed of external technical experts, hosted by WHO Department of Essential Medicines and Pharmaceutical Policies, to review the potential risks/benefits associated with the use of FPPs that are not yet WHO-prequalified or SRA/WLA -authorized and to advise the Global Fund in its decision on whether to allow grant funds to be used to procure FPP. ERP reviewed products can be procured for a limited time (maximum 12 months).

However, under certain circumstances, it is possible to extend the recommendation period. Contracts to supplier/manufacturer for an ERP reviewed products should not be longer than the validity period of the recommendation of that product. For detail information on ERP process and Quality Assurance information, please look at

<https://www.theglobalfund.org/en/sourcing-management/quality-assurance/>.

Procurement of ERP Reviewed Products: Principal Recipients (PRs) must inform the concerned Fund Portfolio Manager (FPM) at the Global Fund in writing by filling the "Notification Form" (available on website) if they intend to procure

ERP-reviewed product(s). The Global Fund Secretariat will review the notification request and upon issuing a " no objection" letter to the PR for the requested selection, procurement can only proceed.

Important Notes

This List may be used by Principal Recipients of Global Fund grants when considering options with respect to procurement of pharmaceutical products pharmaceutical products subject to the Global Fund Quality Assurance Policy. The list aims at providing countries with information that will assist them in their procurement options. Please note that the list is not designed to be a basis for countries to select medicines to be included in their National Treatment Guidelines or to replace any applicable and legally required procurement processes. The Global Fund requires its grant recipients to comply with applicable procurement laws and provides the list only for the **identification of products/manufacturers that comply with the Global Fund's quality assurance policy**. It is important to note that there is no strict requirement to procure according to the list, as long as the Principal Recipients can ensure that the product selected is compliant with the Quality Assurance policy criteria. Furthermore, the Principal Recipient should not rely solely on the information provided in the list but should obtain evidence of products compliance with the Quality Assurance policy. For the above reasons, **we strongly encourage users to ensure they are using the most recent version on our website when conducting procurement.**

The Lists will be updated regularly based on evidence received by the Global Fund. Interested parties are invited to supply information and evidence of products meeting the policy criteria on an ongoing basis. For the above reasons, **we strongly encourage users to ensure they are using the most recent version on our website when conducting procurement.**

According to the Global Fund QA policy, if there are two or more A or B or C classified manufacturers available for any given product AND the product is available from these manufacturers (available-means that the manufacturer can supply the selected product within 90 days after receiving the Purchase Order), then such product must be procured from A or B classified product manufacturers. The PR must notify by writing to the Global Fund Secretariat (Fund Portfolio Manager) and receive the "No Objection" letter from GF secretariat before procuring any products complying with option " ERP Reviewed".

For ease of reference, each "product" with similar formulation and dosage has been identified in this list with a unique "Product reference number" (Column A). Please see examples below.

However, different dosage forms may be grouped under the same Product Reference Number and therefore will be considered the same type of products when identifying the number of available manufacturers for the application of this policy. These products share the same dosing protocol, target the same population, and there are no significant differences among them regarding interchangeability. For example, within solid forms, some capsules will have same reference number as tablets while within liquids, oral solution and suspension are grouped together. Following the same principles, the entero coated tablet or dispersible tablet will not share the same reference number as a normal tablets.

Product Ref.No	International Non-proprietary name	Strength	Dosage form	Supplier/Manufacturer *	Global Fund QA Standard	WHO Pre-qualified/SRA/WLA	Manufacturing site*	Country	Material	Pack
M16	XYZ	50mg	Tablet	"Pharma Company A"	A - B	Yes	"Pharmaville"	Country A	HDPE bottle	60
M17		100mg	Tablet	"Pharma Company B"	A - B	Yes	"Pharmaville"	Country B	HDPE bottle	60

The example above shows 2 different variants of the same medicine. Because the strength is different, it is considered 2 different products (there are two different reference numbers M16 and M17). If the strength had been the same but the dosage form had been different (i.e. tablet and liquid) it would also have been considered two different "products".

Product Ref.No	International Non-proprietary name	Strength	Dosage form	Supplier/Manufacturer*	Global Fund QA Standard	WHO Pre-qualified/SRA/WLA	Manufacturing site*	Country	Packaging	
									Material	Pack
M25	ABC	150mg	Tablet	"Pharma Company A"	A - B	Yes	"Pharmaville"	Country A	Blister, HDPE bottle	10, 60
			Capsules	"Pharma Company B"	A - B	Yes	"Pharmaville"	Country B	HDPE Bottle, Blister	60, 10

In this second example both products have same reference number (M25) because both manufacturers are supplying the same strength and the dosage forms are considered similar as per explanation above.
*** See below**

Disclaimer:

The Global Fund does not endorse or warrant the fitness of any product on the List for a particular purpose, including in regard of its safety and/or efficacy in the treatment of HIV/AIDS, tuberculosis or malaria. In addition, the Global Fund assumes no responsibility for any misstatement or omission from the list and directs Principal Recipients of Global Fund grants to conduct their own independent confirmation that the information on a given product on the list is accurate before relying on it to make a purchase order for that product, and to ensure that any purchase is in compliance with all the requirements of the Global Fund's quality assurance policy. The Global Fund does not warrant or represent that the products listed have obtained regulatory approval for use of treatment of any disease in any particular country of the world, or that their use is otherwise in accordance with the national laws and regulations of any country, including, but not limited to, intellectual property laws. The Global Fund disclaims any and all liability and responsibility for any injury, death, damage or loss of any kind whatsoever that may arise as a result of, or in connection with the procurement, distribution and use of any product included in the list.

*** As from the version 89, please note that we consider under**

**Supplier / Manufacturer :
Marketing authorization/ product authorization or license holder**

**Manufacturing Site:
The Site responsible for the release of the FPP.**

List of A or B or C products:

**If there are two or more 'A' or 'B' products available, then the product must be procured from one of the A or B or C products.
Note: if the product intended for selection is not listed in this list , please refer to the List of ERP (Expert Review Panel) Reviewed Products which are permitted for time limited procurement:**

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
M1	Artesunate	30 mg	Powder for injection	Guilin Pharmaceutical Co. Ltd	A	Yes	Guilin, Guangxi,	China	Glass Vial	Vial; 1 vial of artesunate powder is co-packed with 1 ampoule of sodium bicarbonate injection (0.5mL:25mg) and 1 ampoule of sodium chloride injection (2.5mL:22.5mg)

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
M2	Artesunate	60 mg	Powder for injection	Guilin Pharmaceutical Co. Ltd	A	Yes	Guilin, Guangxi,	China	Glass Vial	Vial [1 vial of artesunate powder is co-packed with 1 ampoule of sodium bicarbonate injection (1ml:50mg) and 1 ampoule of sodium chloride injection (5ml:45mg)]
	Artesunate	60 mg	Powder for injection	Ipca Laboratories Ltd	A	MA135	Ipca Laboratories Ltd, Sejavta, Ratlam, Madhya Pradesh, 457 002	India	Glass Vial	Powder, solvent and diluent for solution for injection 60mg + 5%w/v + 0.9%w/v-1ml of sodium bicarbonate 5% w/v, ampoule: 5ml of sodium chloride 0.9% w/v
	Artesunate	60 mg	Powder for injection	Macleods Pharmaceuticals Ltd, 304 Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai, 400 059, India	A	MA152	Macleods Pharmaceuticals Ltd, Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210, India & Immacule Lifesciences Pvt Limited Village Thantheval, Ropar Road, Nalagarh, Dist.-. Solan Himachal Pradesh - 174101	India	Glass Vial	Vial, glass 10mlx1 (artesunate powder); Ampoule, glass 1mlx1 (sodium bicarbonate); Ampoule, glass 5mlx1 (sodium chloride)
	Artesunate	60 mg	Powder for injection	Guilin Pharmaceutical Co. Ltd	A	MA168	Guilin Pharmaceutical Co Ltd INJ-I & INJ-II, No 43 Qilidian Road Guilin, Guangxi 541 004 China	China	Glass vial	Vial glass 5mlx1 (artesunate powder); Ampoule, glass 3mlx1 (solvent : arginine and Sodium bicarbonate)
M3	Artesunate	120 mg	Powder for injection	Guilin Pharmaceutical Co. Ltd	A	Yes	Guilin, Guangxi,	China	Glass Vial	1 vial of artesunate powder is co-packed with 1 ampoule of sodium bicarbonate injection and 1 ampoule of sodium chloride injection 0.9% w/v + 5% w/v

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Artesunate	120 mg	Powder for injection	Ipca Laboratories Ltd	A	MA186	Ipca Laboratories Ltd P.O. Sejavta Ratlam, Madhya Pradesh 457 002 India	India	Glass Vial	Vial; 1 vial of artesunate powder is co-packed with 1 ampoule of sodium bicarbonate injection (2mL:100mg) and 1 ampoule of sodium chloride injection (10mL:90mg)
	Artesunate	120 mg	Powder for injection	Macleods Pharmaceuticals Ltd	A	MA194	Macleods Pharmaceuticals Ltd Unit 2, Phase I, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam Daman, 396 210 India	India	Glass vial	1 vial of artesunate powder is co-packed with 2 ampoules of sodium bicarbonate injection (1mL:50mg) and 2 ampoules of sodium chloride injection (5mL:45mg)

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
M4	Artemether + Lumefantrine (FDC)	20 mg+120 mg	Tablet	Novartis Pharma	A - B	Yes	Beijing; Suffern Philadelphia Istambul	China USA Turkey	Blister	6, 12, 18, 24
	Artemether + Lumefantrine (FDC)	20 mg+120 mg	Tablet	Ajanta Pharma	A	MA111	Ajanta Pharma Limited Z/103/A, Dahej SEZ-II, Bharuch Gujarat 392130 India Ajanta Pharma Ltd B4/5/6 MIDC Industrial Area, Paithan District Chhatrapati Sambhajnagar, Maharashtra 431 148 India	India	PVC/PVdC/Alu blister	6x1, 12x1, 18x1, 24x1, 6x30, 12x30, 18x30, 24x30
	Artemether + Lumefantrine (FDC)	20 mg+120 mg	Tablet	Cipla Ltd.	A	MA064	Patalganga; Himachal Pradesh, Goa Kurkumbh, Indore; Quality Chemical Industries Ltd, Kampala,	India Uganda	PVC- PCTFEE/Alu Blister Alu-Alu Blister	6, 12, 18, 24
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli,	India	Alu/PVC/PV DC Blister	6, 12, 18, 24
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Tablet	Strides Arcolab Limited	A	MA088	Universal Corporation Ltd, PO Box 1748, Club Road, Plot No 13777, Kikuyu, 902, Kenya Strides Pharma Science Limited, Oral Solid Dosage Forms Division, KRS Gardens, 36/7, Suragajakkanahalli, Indlawadi Cross, Anekal Taluk, Bangalore, Karnataka, 562 106, India	India	PVC/PE/PVD C/Alu blister	1x6; 4x6; 30x6; 30x12; 30x18; 30x24
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Tablet	Macleods	A	MA091	Kachigam Daman Oxalis lab, Baddi Solan Dist	India	Blister Al/PVC/PE/P VDC Blister Al/PVC/Aclar blister	blister 3 x 8; 1 x 6, 2 x 6, 3 x 6, 4 x 6, 30x6, 1x12, 2x12, 1x18, 30x18, 1x24, 30x24

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Tablet	Mylan Labs	A	MA099	<p>Mylan Laboratories Ltd, F4 & F12 Malegaon MIDC, Sinnar, Nashik District, Maharashtra, 422 113, India</p> <p>Mylan Laboratories Limited Lusaka Zambia</p>	India, Zambia	Blister: Alu/Alu; Alu/PVC/Aclar; Alu/PVC/PE/ PVdC	6x1, 6x2, 6x3, 6x4; 18x1; 24x1; 18x10;24x10;18x30 ; 24x30

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
M5	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Dispersible tablets	Novartis Pharma	A	Yes	Rockford, Illinois Conshohocken, Pennsylvania Suffern Istanbul Beijing	USA Turkey China	PVC/Alu blister or PVC/PCTFE/Alu blister	6*30; 12*30; 18*30
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Dispersible tablets	Ajanta Pharma	A	MA092	Ajanta Pharma Limited Z/103/A, Dahej SEZ-II, Bharuch Gujarat 392130 India Ajanta Pharma Ltd B4/5/6 MIDC Industrial Area, Paithan District Chhatrapati Sambhajnagar, Maharashtra 431 148 India	India	PVC/PVdC/Alu blister	6x1, 12x1; 6x30, 12x30
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Dispersible tablets	Strides Shasun Limited	A	MA110	Universal Corporation Ltd, PO Box 1748, Club Road, Plot No 13777, Kikuyu, 902, Kenya Strides Pharma Science Limited, Oral Solid Dosage Forms Division, KRS Gardens, 36/7, Suragajakkanahalli, Indlawadi Cross, Anekal Taluk, Bangalore, Karnataka, 562 106, India	India	Alu/PVC/PVdC	1x6; 1x12; 30x6; 30x12
	Artemether + Lumefantrine	20mg+120mg	Dispersible Tablet	IPCA Laboratories Ltd	A	MA136	Ipca Laboratories Ltd - Plot No : 255/1, Village Athal, Dadra and Nagar Haveli (U.T), Silvassa – 396 230, India Ipca Laboratories Limited, 1 Pharma Zone, SEZ Indore, Pithampur, Madhya Pradesh, 454775, India	India	Alu-Alu blister and PVC/ACLAR/PVC-Alu blister	1 x 6's 1 x 12's 30 x 1 x 6's 30 x 1 x 12's 30 x 6's 30 x 12's
	Artemether + Lumefantrine	20mg+120mg	Dispersible Tablet	Cipla Limited	A	MA115	Cipla Ltd, Unit IV, Plot No 9, 10 & 15 Indore Special Economic Zone, Phase II, Pithampur, Dhar District, Madhya Pradesh, 454 775, India	India	Alu/PVC/Aclar/PVC blister	6x1;12x1;18x1;6x30 ;12x30;18x30

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Artemether + Lumefantrine	20mg+120mg	Dispersible Tablet	Macleods Pharmaceuticals Ltd	A	MA137	Oxalis Labs, Vill. Theda, P.O.Lodhimajra, Baddi, Distt. Solan	India	Bilster, Alu-PVC/PE/PVdC	17x6; 30x6; 30x12
M6	Artemether + Lumefantrine (FDC)	40 mg + 240 mg	Tablet	Mylan Labs	A	MA100	Mylan Laboratories Ltd, F4 & F12 Malegaon MIDC, Sinnar, Nashik District, Maharashtra, 422 113, India	India	Blister: Alu/Alu; Alu/PVC/Aclar; Alu/PVC/PE/PVdC	6x1, 6x2, 6x3, 6x4; 18x1; 24x1; 18x10;24x10;18x30 ; 24x30
	Artemether + Lumefantrine (FDC)	40 mg + 240 mg	Tablet	Ajanta Pharma	A	MA128	Ajanta Pharma Limited Z/103/A, Dahej SEZ-II, Bharuch Gujarat 392130 India Ajanta Pharma Ltd B4/5/6 MIDC Industrial Area, Paithan District Chhatrapati Sambhajanagar, Maharashtra 431 148 India	India	Alu/PVC-PVdC, Blister	6x1; 6x30
	Artemether + Lumefantrine	40mg+240mg	Tablet	Cipla Limited	A	MA120	Vill. Malpur, Baddi, Distt. Solan (H.P.) 173205	India	Alu/PVC/Aclar/PVC blister	6x1
	Artemether + Lumefantrine	40mg +240mg	Tablet FDC	Macleods Pharmaceuticals Ltd	A	MA143	Oxalis Labs Village Theda, P.O Lodhimajra, Baddi, Distt. Solan, Himachal Pradesh, 174101	India	Alu/PVC/PE/PVDC Blister	10x10; 6x30; 6x1
M31	Artemether + Lumefantrine (FDC)	60 mg + 360 mg	Tablet	Ajanta Pharma	A	MA129	Ajanta Pharma Limited Z/103/A, Dahej SEZ-II, Bharuch Gujarat 392130 India Ajanta Pharma Ltd B4/5/6 MIDC Industrial Area, Paithan District Chhatrapati Sambhajanagar, Maharashtra 431 148 India	India	Alu/PVC-PVdC, Blister	6x30; 6x1
	Artemether + Lumefantrine	60mg+360mg	Tablet	Cipla Limited	A	MA121	Vill. Malpur, Baddi, Distt. Solan (H.P.) 173205	India	Alu/PVC/Aclar/PVC blister	6x1
M7	Artemether + Lumefantrine (FDC)	80 mg + 480 mg	Tablet	Ajanta Pharma	A	MA130	Ajanta Pharma Limited Z/103/A, Dahej SEZ-II, Bharuch Gujarat 392130 India Ajanta Pharma Ltd B4/5/6 MIDC Industrial Area, Paithan District Chhatrapati Sambhajanagar, Maharashtra 431 148 India	India	Alu/PVC-PVdC, Blister	6x30; 6x1

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Artemether + Lumefantrine (FDC)	80 mg + 480 mg	Tablet	Novartis Pharma	A	Yes	Ramapo, Rockland County Philadelphia, Pennsylvania Rockford, Illinois Istanbul	USA; Turkey	PVC/PE/PVD C/Alu blister	1x6
	Artemether + Lumefantrine	80mg+480mg	Tablet	Cipla Limited	A	MA122	Vill. Malpur, Baddi, Distt. Solan (H.P.) 173205	India	Alu/PVC/Aclar/PVC blister	1x6
	Artemether + Lumefantrine	80mg+480mg	Tablet, film coated	Macleods Pharmaceuticals Ltd	A	MA142	Oxalis Labs, Vill. Theda, P.O.lodhimajra, Baddi, Distt. Solan	India	Blister Alu/PVC/PE/PVdC	10x15; 30x6; 1x6
	Artemether + Lumefantrine	80mg+480mg	Tablet FDC	Strides Pharma Global PTE Limited	A	MA138	Strides Pharma Science Limited, Oral Solid Dosage Forms Division, KRS Gardens, 36/7, Suragajakkanahalli, Indlawadi Cross, Anekal Taluk, Bangalore, Karnataka, 562 106, India Universal Corporation Ltd, PO Box 1748, Club Road, Plot No 13777, Kikuyu, 902, Kenya	India	PVC/PE/PVDC blister	1x6; 30x6
M33	Artesunate	100mg	Suppository	Cipla Limited	A	MA124	Cipla Limited, D7, MIDC Industrial area Kurkumbh Dist Pune 413802 INDIA	India	Alu/Alu Blister	2'
	Artesunate	100 mg	Suppository	Strides Shasun Ltd - India	A	MA123	Strides Shasun ltd- 36/7, Suragajakkanahalli Indlavadi Cross, Anekal Taluk Bangalore	India	Alu/Alu (Alu foil/OPA/Alu /PVC) blister	2'
M10	Artesunate + Pyronaridine	60mg+180mg	Tablet	Shin Poong Pharmaceutical Co., Ltd, S.Korea	A-B	EMA Art 58 H-W-2319	Shin Poong Pharmaceutical Co., Ltd,Gyeonggi-do	S.Korea	Aluminium/PVC/Aluminium-OPA foil blisters	90(9'sx10)
M11	Artesunate + Pyronaridine	20mg+60mg	granules	Shin Poong Pharmaceutical Co., Ltd, S.Korea	A-B	EMA Art 58 H-W-2319-3	Shin Poong Pharmaceutical Co., Ltd,Gyeonggi-do	S.Korea	Sachet	90
M12	Amodiaquine+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Sanofi Aventis	A	Yes	Maphar Lab,Casablanca	Morocco	Al/Alu Blister	3*1, 3*25
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli	India	Al/Alu Blister	10x1x3; 25x3

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Guilin Pharmaceutical Co. Ltd	A	MA083	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Alu/PA/Alu/PVC blister	1x3; 25x3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Cipla Ltd.	A	MA102	Unit 1, Plot A-33, A-37 & A-2 MIDC Industrial Area, Patalganga, Raigad District, Maharashtra, 410 220, India Unit 2, Plot A-42 MIDC Industrial Area, Patalganga, Raigad District, Maharashtra, 410 220, India	India	Blister	1x3; 25x3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Micro Labs Ltd	A	MA132	Plot No. S-155 to S-159 & N1, Phase III & Phase IV, Verna Industrial Estate, Verna, Goa, 403 722	India	Blister,Alu/Alu; Blister, Alu-PVC/Aclar	1x3, 10x3, 25x23
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Macleods Pharmaceuticals Ltd	A	MA125	Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210	India	Blister;Alu/Alu	1x3s, 25x3s or 10x10s tablets
M13	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Micro Labs Ltd	A	MA133	Plot No. S-155 to S-159 & N1, Phase III & Phase IV, Verna Industrial Estate, Verna, Goa, 403 722	India	Blister,Alu/Alu; Blister, Alu-PVC/Aclar	3x1, 3x10, 3x25
	Amodiaquine+Artesunate (FDC)	135 mg + 50 mg	Tablet	Sanofi Aventis	A	Yes	Maphar Lab,Casablanca	Morocco	Al/Alu Blister	1*3, 25*3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli,	India	Al/Alu Blister	10x1x3; 25x3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Guilin Pharmaceutical Co. Ltd	A	MA084	Guilin, Guangxi, China	China	Alu/PA/Alu/PVC blister	1x3; 1x25

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Cipla Ltd.	A	MA103	Unit 1, Plot A-33, A-37 & A-2 MIDC Industrial Area, Patalganga, Raigad District, Maharashtra, 410 220, India Unit 2, Plot A-42 MIDC Industrial Area, Patalganga, Raigad District, Maharashtra, 410 220, India	India	Blister	1x3; 25x3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Macleods Pharmaceuticals Ltd	A	MA126	Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210	India	Blister;Alu/Alu	1x3s, 25x3s or 10x10's tablets
M14	Amodiaquine+Artesunate (FDC)	270 mg +100 mg	Tablet	Sanofi Aventis	A	Yes	Maphar Lab,Casablanca, Morocco; Rottendorf Pharma, Ennigerloh, Germany; Batch released by: I41Sanofi-Aventis Maroc, Casablanca, Morocco	Morocco Germany	Al/Alu Blister	3*1, 3*25,6*1, 6*25
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli,	India	Al/Alu Blister	10x1x3; 10x1x6; 25x3; 25x6
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Guilin Pharmaceutical Co. Ltd	A	MA085	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Alu/PA/Alu/PVC blister	1x3; 25x3; 1x6; 25x6
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Cipla Ltd.	A	MA104	Unit 1, Plot A-33, A-37 & A-2 MIDC Industrial Area, Patalganga, Raigad District, Maharashtra, 410 220, India Unit 2, Plot A-42 MIDC Industrial Area, Patalganga, Raigad District, Maharashtra, 410 220, India	India	Blister	1X3; 1X6; 25x3; 25x6

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Micro Labs Ltd	A	MA133	Plot No. S-155 to S-159 & N1, Phase III & Phase IV, Verna Industrial Estate, Verna, Goa, 403 722	India	Blister,Alu/Alu; Blister, Alu-PVC/Aclar	3x1, 3x10, 3x25, 6x1, 6x10, 6x25; 3x1, 3x10, 3x25, 6x1, 6x10, 6x25
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Macleods Pharmaceuticals Ltd	A	MA127	Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210	India	Blister;Alu/Alu	10x10, 1x3, 1x6, 25x3, 25x6
M34	Amodiaquine (as Hydrochloride) +(Sulfadoxine+Pyrimethamine)	150mg+ (500mg/25mg)	Co-Blistered tablet	Guilin Pharmaceuticals	A	MA098	Guilin Pharmaceuticals Co. Ltd, No. 43 Quilidian road, Guilin	China	Blister	50x(3+1) 25x(3+1)
M35	Amodiaquine (as Hydrochloride) + Sulfadoxine/ Pyrimethamine	153mg +500mg/ 25mg	Co-blistered Disp tablet	Guilin Pharmaceuticals	A	MA117	Guilin Pharmaceuticals Co. Ltd, No. 43 Quilidian road, Guilin	China	Alu/PVC Blister	50x (3+1)
	Amodiaquine (as Hydrochloride) +(Sulfadoxine+Pyrimethamine)	150mg+ (500mg/25mg)	Dispersible tablet	S Kant Healthcare Ltd, Mumbai, India	A	MA147	S Kant Healthcare Limited, Plot No. 1802-1805, G.I.D.C, Phase III, Vapi, Gujarat, 396195, India	INDIA	Alu-PVC/PVdC co-blister	25', 50'
	Amodiaquine + Pyrimethamine/Sulfadoxine	153mg+25mg/500 mg	Co-blistered dispersible tablet	Macleods Pharmaceuticals Ltd	A	MA171	Macleods Pharmaceuticals Ltd Unit II, Plot No.: 25-27 Survey No.: 366, Premier Industrial Estate, Kachigam, Daman-396210	India	Al/PVC/PVDC C blister	50x (3+1)
	Amodiaquine (as Hydrochloride) + Pyrimethamine/Sulfadoxine	150mg+25mg/500 mg	Co-blistered dispersible tablet	Universal Corporation Ltd	A	MA169	Universal Corporation Ltd PO Box 1748, Club Road, Plot No 13777 Kikuyu, 902 Kenya	Kenya	Blister, Alu/PVDC/PVC	25x (3+1); 30x (3+1); 50x (3+1)

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Amodiaquine (as Hydrochloride) + Pyrimethamine/Sulfadoxine	153mg+25mg/500 mg	Co-blistered dispersible tablet	IPCA Laboratories Ltd	A	MA190	Ipca Laboratories Ltd Plot No 255/1, Village Athal Silvassa, Dadra and Nagar Haveli Daman and Diu 396230 India	India	Al/PVC blister	25x (3+1); 50x (3+1)
M36	Amodiaquine (as Hydrochloride) + Sulfadoxine/ Pyrimethamine	76.5mg+ 250mg/ 12.5mg	Co-blistered Disp tablet	Guilin Pharmaceuticals	A	MA116	Guilin Pharmaceuticals Co. Ltd, No. 43 Quilidian road, Guilin	China	Alu/PVC Blister	50x (3+1)
	Amodiaquine (as Hydrochloride) + Sulfadoxine/ Pyrimethamine	75mg + 250mg/ 12.5mg	Dispersible tablet	S Kant Healthcare Ltd, Mumbai, India	A	MA146	S Kant Healthcare Limited, Plot No. 1802-1805, G.I.D.C, Phase III, Vapi, Gujarat, 396195, India	INDIA	Alu-PVC/PVdC co-blister	25', 50'
	Amodiaquine + Pyrimethamine/Sulfadoxine	76.5mg + 12.5mg/250mg	Co-blistered dispersible tablet	Macleods Pharmaceuticals Ltd	A	MA170	Macleods Pharmaceuticals Ltd Unit II, Plot No.: 25-27 Survey No.: 366, Premier Industrial Estate, Kachigam, Daman-396210	India	Al/PVC/PVD C blister	50x (3+1)
	Amodiaquine (as Hydrochloride) + Pyrimethamine/Sulfadoxine	75mg + 12.5mg/ 250mg	Co-blistered dispersible tablet	Universal Corporation Ltd	A	MA172	Universal Corporation Ltd PO Box 1748, Club Road, Plot No 13777 Kikuyu, 902 Kenya	Kenya	Blister, Alu/PVDC/PVC	25x (3+1); 30x (3+1); 50x (3+1)
	Amodiaquine (as Hydrochloride) + Pyrimethamine/Sulfadoxine	76.5mg + 12.5mg/250mg	Co-blistered dispersible tablet	IPCA Laboratories Ltd	A	MA189	Ipca Laboratories Ltd Plot No 255/1, Village Athal Silvassa, Dadra and Nagar Haveli Daman and Diu 396230 India	India	Al/PVC blister	25x (3+1); 50x (3+1)
M15	Artesunate + Mefloquine (Co-Blistered)	200 mg + 250 mg	Tablet	Mepha	B	Yes	Dornacherstrasse, Aesch	Switzerland	Co-blister	3+6
M16	Artesunate+ Mefloquin (as Hydrochloride) (FDC)	25mg+50mg	Tablet	Cipla Ltd.	A	Yes	Patalganga	India	Alu/Alu strip	1x3, 2x3

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
M17	Artesunate+ Mefloquin (as Hydrochloride) (FDC)	100mg+200mg	Tablet	Cipla Ltd.	A	Yes	Patalganga	India	Alu/Alu strip	1x3, 2x3
M21	Chloroquine (as Phosphate)	250mg as phosphate (155mg as base)	Tablet	Alliance Pharmaceuticals, UK	B	Yes	AndersonBrecon (UK) Limited,	UK	HDPE Bottle; Blister	100; 20
	Chloroquine (as Phosphate)	250mg as phosphate (155 mg as base)	Sugar coated Tablet	Remedica	B	Cyprus MA 012096	Limassol	Cyprus	PP/PE/ Bottle Al/PVC Blister	100, 500, 1000 10*10 tabs; (100*10 tabs)
M22	Mefloquine	250mg	Tablet	Acino	B	Yes	Liesberg	Switzerland	Blister	8
	Mefloquine	250mg	Tablet	Roche, UK	B	Yes	Roche Welwyn Garden City	UK	Blister	8
	Mefloquine	250mg	Tablet	LTT Pharma Lexon UK	B	Yes	Hoffmann-LA Roche	Swiss	Blister	8
	Mefloquine	250mg	Tablet	Mepha Pharma AG, Basel	B	Yes	Acino Pharma AG, Aesch	Switzerland	Blister	4, 6, 8
M23	Dihydroartemisinin/Piperaquine phosphate	20mg +160mg	Film coated Tablet	Alfasigma S.p.A	A-B	MA093	Pomezia	Italy	PVC/PVdC/Alu blister	3
	Dihydroartemisinin/Piperaquine phosphate	20mg +160mg	Disp tablet FDC	Guilin	A	MA141	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Blister, PA/Alu-PVC/Alu	3x25; 3x2
M39	Dihydroartemisinin/Piperaquine phosphate	40mg +320mg	Disp tablet FDC	Guilin	A	MA139	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Blister, PA/Alu-PVC/Alu	3x25; 3x2
M40	Dihydroartemisinin/Piperaquine phosphate	80mg + 640mg	Tablet FDC	Guilin	A	MA140	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Blister, PA/Alu-PVC/Alu	1x6; 25x6
M24	Dihydroartemisinin/Piperaquine phosphate	40mg +320mg	Tablet FDC	Guilin	A	MA131	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Blister, PA/Alu-PVC/Alu	1x9's; 25x9's; 1x6's; 2x6's
	Dihydroartemisinin/Piperaquine phosphate	40mg + 320mg	Film coated Tablet	Alfasigma S.p.A	A-B	MA094	Pomezia	Italy	PVC/PVdC/Alu blister	3, 6 ,9, 12
	Dihydroartemisinin/Piperaquine phosphate	40mg + 320mg	Film coated Tablet	Beijing Holley-Cotec Pharmaceuticals Co Ltd	A	MA177	KBN-Zhejiang Pharmaceutical Co., Ltd. 340 Yunhai Road, Economy Development Zone Jiaxing City, Zhejiang	China	Blister, Alu/PVC	2x6 1x6, 2x6, 1x9, 25x6 , 25x9
M41	Dihydroartemisinin/Piperaquine phosphate	60mg/480mg	Tablet, Film-coated	Guilin	A	MA151	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Blister, PA/Alu-PVC/Alu	6x25; 1x6

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
M42	Dihydroartemisinin/Piperaquine phosphate	30mg +240mg	Disp tablet FDC	Guilin	A	MA157	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Polyamide(PA)/Aluminium/Polyvinyl Chloride(PVC)/Aluminium blister	25x3; 2x3
M25	Primaquine	7.5mg (as base) (equivalent to 13.2mg Primaquine Phosphate)	Film coated Tablet	Remedica	B	Yes	Limassol	Cyprus	PP/PE/ Bottle Al/PVC Blister	100; 1000 10*10 tab, 10*100 tab
M26	Primaquine	15mg (as base) (equivalent to 26.3mg Primaquine Phosphate)	Tablet	Sanofi / Valeant Pharmaceuticals	B	Yes	Laval, Quebec	Canada	HDPE bottle	100
	Primaquine	15mg (as base)	Tablet	Macleods Pharmaceuticals Limited	B	MA176	Macleods Pharmaceuticals Ltd. Block N2, Village Theda, Post Office Lodhimajra, Tehsil Baddi, Distt. Solan, Himachal Pradesh, 174101	India	Al/Al blister HDPE bottle	10x10 100
M30	Proguanil	100mg	Tablet	Alliance Pharma (Ireland) Ltd	B	Yes	ANDERSONBRECON (UK) LIMITED WYE VALLEY BUSINESS PARK BRECON ROAD, HAY-ON-WYE, HEREFORD HEREFORDSHIRE, HR3 5PG	UK	HDPE Bottle; Blister	100; 98
M27	Quinine Di Hydrochloride	300 mg/ml (600 mg/2 ml or 30 %)	Injectable solution- Route of administration- IV	Renaudin Laboratoire	B	French AMM 354 009-1 and 354 013-9	Zone Artisanale Errobi	France	Ampoule	10, 100
M28	Quinine Sulphate	300 mg	Film coated Tablet	Remedica	B	Yes	Limassol	Cyprus	P/P Container/ Al/PVC Blister	100, 1000 10*10 tabs; 10*100 tabs

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Quinine Sulphate	300 mg (248mg of quinine base)	Film coated Tablet	Strides Pharma UK Ltd	B	PL 13606/0058	Strides Pharma UK Ltd. Unit 4, Metro Centre Tolpits Lane, Watford, Hertfordshire, WD18 9SS United Kingdom	UK	Al/PVC blister packs	2x14tabs, (box of 28 tabs)
M29	Sulfadoxine/Pyrimethamine	250mg/12.5mg	Disp. Tablet	Macleods Pharmaceuticals Ltd, 304 Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai, 400 059, India	A	MA158	Macleods Pharmaceuticals Ltd, Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210, India	India	Blister Alu-PVC/PVDC	11x10; 3x1; 3x10; 3x25; 3x50; 3x100
	Sulfadoxine/Pyrimethamine	250mg/12.5mg	Disp. Tablet	S Kant Healthcare Ltd, Mumbai, India	A	MA144	S Kant Healthcare Limited, Plot No. 1802-1805, G.I.D.C, Phase III, Vapi, Gujarat, 396195, India	India	Blister, Alu-PVC/PVDC	1x3's, 10x3's, 25x3's, 50x3's, 100x3's, 11x10's
	Sulfadoxine/Pyrimethamine	250mg/12.5mg	Dispersible tablet	Universal Corporation Limited	A	MA166	Universal Corporation Limited Club Road, Plot No. 13777 P.O. Box 1748-00902 Kikuyu	Kenya	Al/PVDC blister	10x3's; 100x3's; 50x3's
	Sulfadoxine/Pyrimethamine	250mg/12.5mg	Dispersible tablet	Guilin Pharmaceutical Co. Ltd	A	MA178	Guilin Pharmaceutical Co., Ltd. OSD, No 43 Qilidian Road Guilin, Guangxi 541 004 China	China	Blister; Alu/PVC	1x3'; 10x3'; 50x3'; 100x3'
	Sulfadoxine/Pyrimethamine	250mg/12.5mg	Dispersible tablet	IPCA Laboratories Ltd	A	MA191	Ipca Laboratories Ltd Plot No 255/1, Village Athal Silvassa, Dadra and Nagar Haveli Daman and Diu 396230 India	India	Blister; Alu/PVC	10x3'; 50x3'; 100x3'
M33	Sulfadoxine/Pyrimethamine	500mg/25mg	Tablet	Guilin Pharmaceuticals	A	MA113	Guilin Pharmaceuticals Co. Ltd, No. 43 Quilidian road,	China	HDPE bottle; Blister	100's,1000's 1x3; 10x3; 50x3, 100x3

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Sulfadoxine/Pyrimethamine	500mg/25mg	Tablet	Remedica	B	Yes	Limassol	Cyprus	Al/PVC blister PE container	1*3 tabs and , 10* 3tabs 100's and 1000's
	Sulfadoxine/Pyrimethamine	500mg/25mg	Disp. Tablet	Macleods Pharmaceuticals Ltd, 304 Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai, 400 059, India	A	MA159	Macleods Pharmaceuticals Ltd, Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210, India	India	Blister Alu-PVC/PVDC	10x10; 3x1; 3x10; 3x50
	Sulfadoxine/Pyrimethamine	500mg/25mg	Disp. Tablet	S Kant Healthcare Ltd, Mumbai, India	A	MA145	S Kant Healthcare Limited, Plot No. 1802-1805, G.I.D.C, Phase III, Vapi, Gujarat, 396195, India	India	Blister, Alu-PVC/PVDC	3x25
	Sulfadoxine/Pyrimethamine	500mg/25mg	Disp. Tablet	Universal Corporation Limited	A	MA163	Universal Corporation Limited Club Road, Plot No. 13777 P.O. Box 1748-00902 Kikuyu	Kenya	Al/PVDC blister	10x3's, 30x3's, 50x3's, 100x3's
	Sulfadoxine/Pyrimethamine	500mg/25mg	Disp. Tablet	Guilin Pharmaceutical Co. Ltd	A	MA179	Guilin Pharmaceutical Co., Ltd. OSD, No 43 Qilidian Road Guilin, Guangxi 541 004 China	China	Blister; Alu/PVC	1x3'; 10x3'; 50x3'; 100x3'
	Sulfadoxine/Pyrimethamine	500mg/25mg	Disp. Tablet	IPCA Laboratories Ltd	A	MA192	Ipca Laboratories Ltd Plot No 255/1, Village Athal Silvassa, Dadra and Nagar Haveli Daman and Diu 396230 India	India	Blister; Alu/PVC	10x3'; 50x3'; 100x3'
	Sulfadoxine/Pyrimethamine	500mg/25mg	Tablet	S Kant Healthcare Ltd	A	MA193	S Kant Healthcare Limited Plot No. 1802-1805, G.I.D.C, Phase III Vapi, Gujarat 396195 India	India	HDPE Bottle Blister, Alu/PVC/PV DC	500's and 1000's 30x3's

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA /WLA	Manufacturing site	Country	Material	Pack
	Sulfadoxine/Pyrimethamine	500mg/25mg	Tablet	Swiss Pharma Nigeria Ltd.	A	MA180	Swiss Pharma Nigeria Ltd. P.O Box 463, Ikeja, 5, Dopemu Road Agege, Lagos 100273 Nigeria	Nigeria	Blister, Alu/PVC	1x3';10x3'; 50x3';
M43	Tafenoquine (1)	150mg	Film-coated tablet	GlaxoSmithKline Australia Pty Ltd	A	MA203	Piramal Pharma Limited Plot No. 67-70, Sector-II Pithampur Dhar District Madhya Pradesh 454 775 India	India	Alu/Alu blister	1x2'
M44	Tafenoquine (1)	50mg	Dispersible tablet	GlaxoSmithKline Australia Pty Ltd	A	MA204	Piramal Pharma Limited Plot No. 67-70, Sector-II Pithampur Dhar District Madhya Pradesh 454 775 India	India	Alu/Alu blister	10x3's
	End of A or B or C products list (1) Refer to WHO guidelines to get more details on WHO recommendations : https://www.who.int/publications/i/item/guidelines-for-malaria									

**List Of Malaria Pharmaceutical Products
classified according to the Global Fund Quality Assurance Policy**

Edition: Version 123 - 05-Feb-2025

List of ERP (Expert Review Panel) Reviewed Products which are permitted for time limited procurement:

If there is no or only one A or B or C product available (supply of the product cannot be done within 90 days after the receipt of the Purchase Order by the manufacturer) , grant funds may be used to procure a ERP reviewed product eligible for procurement for limited time (12 months) period. The PR must send the “notification form” (available at https://www.theglobalfund.org/media/5863/psm_notification_form_en.doc) to the Global Fund and upon receiving the “ No Objection” letter form the Global Fund, the procurement can proceed. Please note that the QC test of the selected ERP product will be performed by the Global Fund.

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	Period Validity for ERP Review	Manufacturing site	Country	Material	Pack
M26	Primaquine	15 mg (as base) (equivalent to 26.3mg Primaquine Phosphate)	Film coated tablet	Ipca Laboratories Ltd.	ERP reviewed	28.nov.25	Ipca Laboratories Ltd. Plot No. 255/1, Village- Athal, Silvassa 396230, Union Territory of Dadra & Nagar Haveli and Daman & Diu, India	India	Al/Al blister	1x7's and 2x7's
	End of ERP Reviewed products list									